Cargando…

Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age. Although promising strides have been made in the field of PCOS over the past decades, the distinct etiologies of this syndrome are not fully elucidated. Prenatal factors, genetic variation, epigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kexin, Li, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622806/
https://www.ncbi.nlm.nih.gov/pubmed/37929034
http://dx.doi.org/10.3389/fendo.2023.1191759
_version_ 1785130623751421952
author Wang, Kexin
Li, Yanhua
author_facet Wang, Kexin
Li, Yanhua
author_sort Wang, Kexin
collection PubMed
description Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age. Although promising strides have been made in the field of PCOS over the past decades, the distinct etiologies of this syndrome are not fully elucidated. Prenatal factors, genetic variation, epigenetic mechanisms, unhealthy lifestyles, and environmental toxins all contribute to the development of this intricate and highly heterogeneous metabolic, endocrine, reproductive, and psychological disorder. Moreover, interactions between androgen excess, insulin resistance, disruption to the hypothalamic–pituitary–ovary (HPO) axis, and obesity only make for a more complex picture. In this review, we investigate and summarize the related molecular mechanisms underlying PCOS pathogenesis from the perspective of the level of signaling pathways, including PI3K/Akt, TGF-β/Smads, Wnt/β-catenin, and Hippo/YAP. Additionally, this review provides an overview of prospective therapies, such as exosome therapy, gene therapy, and drugs based on traditional Chinese medicine (TCM) and natural compounds. By targeting these aberrant pathways, these interventions primarily alleviate inflammation, insulin resistance, androgen excess, and ovarian fibrosis, which are typical symptoms of PCOS. Overall, we hope that this paper will pave the way for better understanding and management of PCOS in the future.
format Online
Article
Text
id pubmed-10622806
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106228062023-11-04 Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome Wang, Kexin Li, Yanhua Front Endocrinol (Lausanne) Endocrinology Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age. Although promising strides have been made in the field of PCOS over the past decades, the distinct etiologies of this syndrome are not fully elucidated. Prenatal factors, genetic variation, epigenetic mechanisms, unhealthy lifestyles, and environmental toxins all contribute to the development of this intricate and highly heterogeneous metabolic, endocrine, reproductive, and psychological disorder. Moreover, interactions between androgen excess, insulin resistance, disruption to the hypothalamic–pituitary–ovary (HPO) axis, and obesity only make for a more complex picture. In this review, we investigate and summarize the related molecular mechanisms underlying PCOS pathogenesis from the perspective of the level of signaling pathways, including PI3K/Akt, TGF-β/Smads, Wnt/β-catenin, and Hippo/YAP. Additionally, this review provides an overview of prospective therapies, such as exosome therapy, gene therapy, and drugs based on traditional Chinese medicine (TCM) and natural compounds. By targeting these aberrant pathways, these interventions primarily alleviate inflammation, insulin resistance, androgen excess, and ovarian fibrosis, which are typical symptoms of PCOS. Overall, we hope that this paper will pave the way for better understanding and management of PCOS in the future. Frontiers Media S.A. 2023-10-19 /pmc/articles/PMC10622806/ /pubmed/37929034 http://dx.doi.org/10.3389/fendo.2023.1191759 Text en Copyright © 2023 Wang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Wang, Kexin
Li, Yanhua
Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
title Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
title_full Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
title_fullStr Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
title_full_unstemmed Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
title_short Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
title_sort signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622806/
https://www.ncbi.nlm.nih.gov/pubmed/37929034
http://dx.doi.org/10.3389/fendo.2023.1191759
work_keys_str_mv AT wangkexin signalingpathwaysandtargetedtherapeuticstrategiesforpolycysticovarysyndrome
AT liyanhua signalingpathwaysandtargetedtherapeuticstrategiesforpolycysticovarysyndrome